BIOMARKERS FOR DIAGNOSING OF PROSTATE CANCER: THE PRESENT AND THE FUTURE

BIOMARKERS FOR DIAGNOSING OF PROSTATE CANCER: THE PRESENT AND THE FUTURE

This review analyze data of clinical trials, systematic reviews and meta-analyses, which evaluated the sensitivity and specificity of any biomarkers using for diagnostics of prostate cancer before an initial prostate biopsy or after a negative initial biopsy.

Bibliographic Details
Main Authors:	L. M. Rapoport, E. A. Bezrukov, R. B. Sukhanov, G. E. Krupinov, D. G. Tsarichenko, G. A. Martirosyan, S. K. Avakyan
Format:	Article
Language:	Russian
Published:	ABV-press 2018-05-01
Series:	Андрология и генитальная хирургия
Subjects:	prostate cancer diagnosis biomarkers biopsy prostate specific antigen
Online Access:	https://agx.abvpress.ru/jour/article/view/281

Similar Items

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
by: Peter Ka-Fung Chiu, et al.
Published: (2016-09-01)

Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects
by: Yutong Liu, et al.
Published: (2025-01-01)

Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy
by: Kwang Suk Lee, et al.
Published: (2017-03-01)

Value of various PSA parameters for diagnosing prostate cancer in men with normal digital rectal examination
by: Ari Miotto Jr, et al.
Published: (2004-04-01)

Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience
by: Safana S. Al Saidi, et al.
Published: (2017-07-01)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?
by: Hasan Deliktaş, et al.
Published: (2017-06-01)

Prostate cancer biomarkers: Are we hitting the mark?
by: Shannon McGrath, et al.
Published: (2016-12-01)

Integrated predictive model for prostatic cancer using clinical, laboratory and ultrasound data
by: GUSTAVO DAVID LUDWIG, et al.

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy
by: Yong Hyun Park, et al.
Published: (2014-03-01)

Incidence of histological prostatitis and its correlation with PSA density
by: Affonso Celso Piovesan, et al.
Published: (2009-11-01)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
by: Gokhan Koc, MD, et al.
Published: (2017-01-01)

Chronic inflammation of the prostate type IV with respect to risk of prostate cancer
by: Antonio B. Porcaro, et al.
Published: (2014-09-01)

Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening
by: Yu Chen, et al.
Published: (2024-09-01)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
by: Jeremy YC Teoh, et al.
Published: (2017-01-01)

How to avoid prostate biopsy in men with Prostate Image-Reporting and Data System 3 lesion? Development and external validation of new biopsy indication using prostate health index density
by: Jae Yeon Kim, et al.
Published: (2023-09-01)

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study
by: Mantica G, et al.
Published: (2022-10-01)

The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements
by: Ingle SP, et al.
Published: (2013-01-01)

Effect on prostatic specific antigen by a short time treatment with a Curcuma extract: A real life experience and implications for prostate biopsy
by: Andrea Fabiani, et al.
Published: (2018-06-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

A Study on TRUS-Guided Prostatic Biopsy and its Correlation with Serum PSA, Gleason Score and Grade-Grouping in a Tertiary Care Centre of Eastern India
by: GOPINATH BARUI, et al.
Published: (2019-03-01)

Effect of Finasteride on PSA and Histopathological Results in Patients Undergoing Prostate Biopsy
by: Saman Farshid, et al.
Published: (2022-12-01)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
by: Marie Christine Hupe, et al.
Published: (2018-12-01)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1)
by: Jun Liu, et al.
Published: (2020-01-01)

Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: Our experience and review of the literature
by: Selcuk Sarıkaya, et al.
Published: (2014-12-01)

Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection
by: Bas Israël, et al.
Published: (2022-09-01)

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study
by: Antonio Benito Porcaro, et al.
Published: (2015-10-01)

Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
by: Matthew J. Roberts, et al.
Published: (2016-09-01)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
by: Tushar Aditya Narain, et al.
Published: (2022-01-01)

Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy
by: Marcos F. Dall'oglio, et al.
Published: (2005-06-01)

The diagnostic importance of biomarkers of angio-genesis and inflammation at patients with prostate diseases
by: Popkov V.M., et al.
Published: (2016-12-01)

Investigation of the Cut-off Value for Prostate-Specific Antigen in Patients referring to Shahid Beheshti Hospital of Babol
by: H Shafi, et al.
Published: (2015-08-01)

Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis
by: S. Fontenete, et al.
Published: (2011-12-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

Ten-core versus 16-core transrectal ultrasonography guided prostate biopsy for detection of prostatic carcinoma: a prospective comparative study in Indian population
by: V. Surya Prakash, et al.
Published: (2013-12-01)

Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey
by: Oktay Uçer, et al.
Published: (2015-10-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)